Showing 1 to 2 of 2 results


Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate
A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.
Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate
A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.
Progress
60% Bias Score

Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit
A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.

Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit
A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.
Progress
52% Bias Score
Showing 1 to 2 of 2 results